%0 Journal Article
%A Weller, Johannes
%A Zeyen, Thomas
%A Schäfer, Niklas
%A Schaub, Christina
%A Potthoff, Anna-Laura
%A Steinbach, Joachim P
%A Hau, Peter
%A Seidel, Clemens
%A Goldbrunner, Roland
%A Tabatabai, Ghazaleh
%A Vatter, Hartmut
%A Tzaridis, Theophilos
%A Schneider, Matthias
%A Herrlinger, Ulrich
%T The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
%J Journal of neuro-oncology
%V 164
%N 3
%@ 0167-594X
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V
%M DKFZ-2023-02005
%P 749-755
%D 2023
%Z 2023 Sep;164(3):749-755
%X The AVAglio trial reported a significant survival benefit for first line bevacizumab treatment in patients with IDH wildtype glioblastoma of the proneural gene expression subtype. We here aim to replicate these findings in an independent trial cohort.We evaluate the treatment benefit of bevacizumab according to gene expression subtypes of pretreatment tumor samples (n = 123) in the GLARIUS trial (NCT00967330) for MGMT unmethylated glioblastoma patients with Kaplan-Meier analyses, log-rank tests and Cox regression models.Employing the Phillips classifier, bevacizumab conferred a significant PFS advantage in patients with proneural IDH wild-type tumors (10.4 vs. 6.0 months, p = 0.002), but no OS advantage (16.4 vs. 17.4 months, p = 0.6). Multivariable analysis adjusting for prognostic covariates confirmed the absence of a significant OS advantage from bevacizumab (hazard ratio, 1.05, 95
%K Bevacizumab (Other)
%K Gene expression (Other)
%K Glioblastoma (Other)
%K Newly diagnosed glioblastoma (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37787906
%R 10.1007/s11060-023-04470-9
%U https://inrepo02.dkfz.de/record/284416